Trial Profile
Thorough QT/QTc trial of RPC 1063 in volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Nov 2017
Price :
$35
*
At a glance
- Drugs Ozanimod (Primary)
- Indications Multiple sclerosis; Ulcerative colitis
- Focus Adverse reactions
- Acronyms TQT
- 28 Oct 2017 Results of analysis assessing cardiac safety of ozanimod in RADIANCE and QT/QTc trials (see CTP 239937) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
- 24 Dec 2013 New trial record
- 05 Jun 2013 Primary endpoint `No significant difference between RPC 1063 and placebo in prolongation of corrected QT interval' has been met, according to a Receptos media release.